COPD

A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.

Interprofessional management of chronic obstructive pulmonary disease should include individualized approaches.

The combination treatment (Duaklir, Circassia) is designed to be administered twice-daily via AstraZeneca’s breath-actuated inhaler (Pressair).

The combination therapy was approved for twice-daily administration via the breath-actuated Pressair inhaler in patients with COPD.

Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.

Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.

The FDA announced approval of Wixela Inhub on January 30, 2019.

The generic product (Wixela Inhub, Mylan) will be offered in 3 strengths at wholesale acquisition costs that are 70% less than the brand equivalent Advair Diskus, according to Mylan.

With new products coming to the pharmacy market, such as smart devices and digital medicines, the profession will need to develop quickly to keep up pace.

Mylan's drug is approved for 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg doses.

The generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease, including bronchitis and emphysema.

Teva has just unveiled the world's first integrated smart inhaler to the market.

Four cases address respiratory illnesses.

A new study indicates that there are age-associated gender differences seen in the disease burden of chronic obstructive pulmonary disorder (COPD), with younger women more severely affected.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

The FDA has approved new labeling for Boehringer Ingelheim's Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray that includes data showing a meaningful reduction in COPD exacerbations driven by tiotropium.

Top news of the day from across the health care landscape.

More than 4 in 10 women with asthma may develop chronic obstructive pulmonary disorder, but many risk factors are modifiable.

Patients with chronic obstructive pulmonary disease and who have other comorbid conditions are undertreated when hospitalized for exacerbations, study finds.

The results of a recent UK study reveal that psychological distress, whether considered low or moderate, can increase a patient’s risk for chronic obstructive pulmonary disease (COPD), arthritis, and cardiovascular disease (CVD).

The results of a recent UK study reveal that psychological distress, whether considered low or moderate, can increase a patient’s risk for chronic obstructive pulmonary disease, arthritis, and cardiovascular disease.

A new device intended to treat breathing difficulty associated with severe emphysema has been approved by the FDA.

Even though patients with advanced chronic obstructive pulmonary disease (COPD) can suffer from the same distressing symptoms as those with end-stage cancer, they are less likely to receive palliative care than those with other terminal illnesses.